Company intelligence / Profile preview
HUTCHMED
Hong Kong SAR, Kowloon, Hong Kongorpha.net ↗
- Ownership
- Public · HCM
- Employees
- ~5000
- Development stage
- Commercial
01
Overview
HUTCHMED has three oncology drugs approved and marketed in China—fruquintinib (Elunate®), savolitinib (Orpathys®), surufatinib (Sulanda®)—with fruquintinib also approved globally. The company’s pipeline spans multiple clinical stages from preclinical to commercial. Fruquintinib has demonstrated efficacy as a VEGFR inhibitor for metastatic colorectal cancer patients who have failed prior therapies. Orpathys targets NSCLC with MET exon 14 skipping mutations. Surufatinib addresses advanced neuroendocrine tumors. Tazverik® for follicular lymphoma was developed by Epizyme but partnered for commercialization outside the US/Japan.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules (notably highly selective oral inhibitors)immunotherapies
- Industry
- Biotech
02
Drug pipeline
25 assets24 more assets in the full pipeline.
Request access →03
Partnerships
Ipsen (global commercialization of certain assets)BeiGene & Innovent Biologics for combination trials with PD‑1 antibodiesAstraZeneca on savolitinib development/commercialization outside Greater China region.
04
Financials
- Market cap
- $2.1B
- Total revenue
- $138.8M
- Enterprise value
- $815.5M
Beyond the preview
Go deeper on HUTCHMED.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUTCHMED.